Core Insights - DAV has formed a strategic partnership with Dexcom to support diabetes care for veterans, marking Dexcom's first collaboration with a nonprofit serving this demographic [1][2] - The partnership aims to address the high prevalence of diabetes among veterans, estimated at around 25%, particularly focusing on Type 2 diabetes [2][3] - DAV's CEO emphasized the increased risk of diabetes among veterans, who are nearly twice as likely to develop the disease compared to the general population [3] Company Overview - DAV is a nonprofit organization dedicated to supporting veterans and their families by helping them access benefits, providing employment resources, and advocating for their needs [5] - Founded in 1920 and chartered by the U.S. Congress in 1932, DAV has nearly 1 million members and offers no-cost services to help veterans [5] Partnership Details - The diabetes resource page, set to launch in early 2026, will provide information on diabetes prevalence and treatment options for veterans [2] - The collaboration aims to empower veterans with knowledge and tools to manage diabetes effectively [3]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against DexCom, Inc. for alleged misrepresentations regarding the accuracy and functionality of its G7 continuous glucose monitoring system, affecting investors who purchased securities between January 8, 2024, and September 17, 2025 [1][3]. Group 1 - The lawsuit claims that the defendants made false statements about the reliability and enhancements of the Dexcom G7 device, as well as the company's manufacturing capabilities [3]. - Investors who acquired DexCom securities during the specified period are encouraged to consider their legal rights and options regarding the class action [2][4]. - The deadline to file as a lead plaintiff in the class action is December 26, 2025, with no fees or expenses required from shareholders [4]. Group 2 - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, indicating a strong track record in this area [5].

Core Insights - DexCom, Inc. has received FDA clearance for Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy [1] - The Dexcom Smart Basal will utilize data from the Dexcom G7 15 Day sensor and logged doses to provide personalized daily recommendations for optimizing long-acting insulin doses [1] Company Summary - DexCom, Inc. is recognized as the global leader in glucose biosensing technology [1] - The introduction of Dexcom Smart Basal represents a significant advancement in diabetes management, specifically targeting adults with Type 2 diabetes [1] Industry Impact - The FDA clearance of Dexcom Smart Basal is expected to enhance the management of Type 2 diabetes, potentially improving patient outcomes through personalized insulin dosing [1]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [6]. - The defendants are accused of making false statements regarding the reliability and functionality of the G6 and G7 devices, leading to increased regulatory scrutiny and potential financial harm [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 29, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that DexCom's public statements regarding the enhancements and reliability of the G7 devices were materially false and misleading, leading to increased regulatory scrutiny and potential legal repercussions [5].

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. to recover losses for shareholders affected by alleged securities fraud between January 8, 2024, and September 17, 2025 [2] - The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users [3] - The complaint claims that the defendants overstated the enhancements and reliability of the G7 device while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential financial harm [3] Case Details - The lawsuit outlines that DexCom's design changes to the G6 and G7 were not authorized by the U.S. Food and Drug Administration [3] - It is alleged that these changes compromised the accuracy of glucose readings, which is critical for users relying on these devices for health management [3] - The complaint indicates that the public statements made by the defendants were materially false and misleading throughout the relevant period [3] Next Steps - Shareholders who suffered losses in DexCom stock during the specified timeframe are encouraged to seek information about their rights to recovery [4] - Participation in the recovery process is stated to be at no cost or obligation to the shareholders [4] Firm Background - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5] - The firm has been ranked among the top securities litigation firms in the United States for seven consecutive years [5] - Levi & Korsinsky has extensive experience in complex securities litigation, with a dedicated team to support clients [5]

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period from January 8, 2024, to September 17, 2025 [1][3]. Group 1: Allegations Against DexCom - The complaints allege that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [3]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [3]. - The allegations suggest that these actions increased DexCom's exposure to regulatory scrutiny and potential legal, reputational, and financial harm [3]. Group 2: Legal Process and Investor Actions - Investors who suffered losses can seek to be appointed as lead plaintiffs by December 26, 2025, or may choose to remain absent class members [4]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [4]. - Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact them for more information regarding the lawsuit [5].

Core Points - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit for alleged misleading statements and undisclosed information related to the company's glucose monitoring products [1][2]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitoring devices, which rendered them less reliable and posed health risks to users [1]. - It is claimed that the enhancements to the G7 device were overstated, and the company downplayed the severity of the issues related to the G7 devices [1]. - The allegations suggest that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [1]. Class Action Details - The class period for the lawsuit is from January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation by December 26, 2025 [2]. - Shareholders who register will receive updates on the case through a portfolio monitoring software [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [2]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users [2]. - DexCom is accused of overstating the enhancements and reliability of the G7 device, downplaying the severity of issues related to adulterated devices [2]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [2]. Group 2: Lead Plaintiff Process - Investors in DexCom can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [3]. - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3]. Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without approval from the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [2]. - Defendants are accused of downplaying the severity of the issues and health risks associated with the altered G7 devices [2]. - The lawsuit suggests that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2]. Group 2: Next Steps for Investors - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].